Patents Examined by Kimberly Ballard
  • Patent number: 10786557
    Abstract: Compositions and methods useful for the treatment of neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) are disclosed.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: September 29, 2020
    Assignee: SHIRE VIROPHARMA LLC
    Inventors: Colin Broom, Jeffrey Dayno
  • Patent number: 10781420
    Abstract: The present invention provides a method for producing a human cell aggregate containing a midbrain-hindbrain boundary neural progenitor tissue, including subjecting an aggregate of human pluripotent stem cells to suspension culturing in a serum-free medium containing insulin, and treating, in the suspension culturing, the aggregate of human pluripotent stem cells or a human cell aggregate derived therefrom with a ROCK inhibitor, a TGF? signal inhibitor, and a first fibroblast growth factor. Furthermore, the human cell aggregate containing the midbrain-hindbrain boundary neural progenitor tissue is subjected to suspension culturing in a serum-free medium to induce formation of a neuroepithelial structure by neural progenitor in the neural progenitor tissue, whereby the human cell aggregate containing the cerebellar plate tissue can be obtained.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: September 22, 2020
    Assignees: RIKEN, SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Yoshiki Sasai, Keiko Muguruma
  • Patent number: 10781421
    Abstract: The present invention pertains to a method for the generation of neurotoxin-sensitive, neuronal differentiated cells comprising the steps of: a) cultivating tumor cells which are able to differentiate into neuronal cells in a culture medium under conditions and for a time which primes said tumor cells for neuronal differentiation; and b) cultivating the tumor cells primed for neuronal differentiation of a) in a differentiation medium having an osmolality of 100 to 270 mOsm/kg, and comprising (i) B27 supplement and/or (ii) N2 supplement, for at least 3 days, thereby obtaining neurotoxin-sensitive, neuronal differentiated cells. The invention further relates to neurotoxin-sensitive, neuronal differentiated cells obtainable by the method of the invention.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: September 22, 2020
    Assignee: MERE PHARMA GmbH & CO. KGaA
    Inventors: Karl-Heinz Eisele, Kai Harting
  • Patent number: 10780131
    Abstract: The present disclosure provides methods for the treatment of a mammal having a neurological condition, disease, or injury. The methods involve increasing the number of functional GABAergic interneurons at or near the site of the neurological disease, injury, or condition.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: September 22, 2020
    Assignee: The Regents of the University of California
    Inventors: Arnold Kriegstein, John L. R. Rubenstein, Scott C. Baraban, Arturo Alvarez-Buylla
  • Patent number: 10772969
    Abstract: The disclosure pertains to N-terminal epitopes identified in A-beta, including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: September 15, 2020
    Assignee: The University of British Columbia
    Inventors: Neil R. Cashman, Steven S. Plotkin
  • Patent number: 10752679
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: August 25, 2020
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour
  • Patent number: 10730937
    Abstract: An anti-HMGB1 antibody comprising a light chain variable region comprising complementarity-determining regions or the like including amino acid sequences of SEQ ID NOs: 4 to 6, and a heavy chain variable region comprising complementarity-determining regions or the like including amino acid sequences of SEQ ID NOs: 10 to 12, or an anti-HMGB1 antibody comprising a light chain variable region or the like comprising an amino acid sequence of SEQ ID NO: 3, and a heavy chain variable region comprising an amino acid sequence or the like of SEQ ID NO: 9, and a composition for treating or preventing Alzheimer's disease, comprising the same as an active ingredient.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: August 4, 2020
    Assignee: National University Corporation Tokyo Medical and Dental University
    Inventors: Hitoshi Okazawa, Masunori Kajikawa
  • Patent number: 10729815
    Abstract: A combined treatment for nerve injury is provided. Accordingly there is provided a composition comprising a hyaluronic acid, a laminin polypeptide, an antioxidant and an anti-gliotic agent. Also provided are matrices and hydrogels of the composition and methods of using same.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: August 4, 2020
    Assignees: Ramot at Tel-Aviv University Ltd., The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center
    Inventors: Shimon Rochkind, Zvi Nevo
  • Patent number: 10729788
    Abstract: In alternative embodiments, provided are methods for increasing levels of and/or upregulating the expression of ApoA-I Binding Protein (APOA1BP, AIBP, or AI-BP) to treat, ameliorate, prevent, reverse, decrease the severity or duration of: a neuropathic pain, including an inflammation-induced neuropathic pain, a nerve or CNS inflammation, a, a post nerve injury pain, a post-surgical pain, a chemotherapeutic-induced peripheral neuropathy (CIPN) (e.g., cisplatin-induced allodynia) a neurodegeneration or neurodegenerative disease or condition, a migraine, and/or a hyperalgesia.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: August 4, 2020
    Assignee: The Regents of the University of California
    Inventors: Yury Miller, Tony L. Yaksh
  • Patent number: 10718784
    Abstract: The present invention is inter alia concerned with a method of diagnosing Alzheimer's disease in a patient, wherein said method is based on determining the amount of at least one premature mitochondrial protein. Further, the present invention relates to the use of such a protein as marker for Alzheimer's disease. Accordingly, antibodies binding to such a preprotein may be used for diagnosing Alzheimer's disease. The present invention is based on the finding that premature mitochondrial proteins accumulate in Alzheimer's disease.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: July 21, 2020
    Assignee: Albert-Ludwigs-Universität Freiburg
    Inventors: Chris Meisinger, Nora Vögtle, Dirk Mossmann, Elzbieta Glaser, Caroline Graff, René P. Zahedi
  • Patent number: 10717965
    Abstract: The present disclosure pertains to a mammalian cell culture genetically modified to express, and which expresses, a neublastin antibody polypeptide, or fragment thereof, in the culture, and to a neublastin antibody polypeptide, or fragment thereof, made by a mammalian cell culture genetically modified to express, and which expresses, the neublastin antibody polypeptide, or fragment thereof.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: July 21, 2020
    Assignee: Gloriana Therapeutics, Inc.
    Inventors: Alan Gilbert, Kyle McElearney, Terrence Michael Dobrowsky, Rashmi Rohit Kshirsagar
  • Patent number: 10718785
    Abstract: Alzheimer's disease (AD) is the most common type of dementia in aging adults with the number of people living with AD projected to increase, making the search for treatments and tools to diagnose and measure disease progression increasingly urgent. In particular, ideal biomarkers for diagnosis of AD should not only have high specificity for disease versus non-disease and high sensitivity for distinguishing between disease types but also should be able to detect changes at a very early stage of the disease. Using microglia activation as an early event of AD's onset, the present inventors have identified a panel of biomarkers in CSF which has the potential to diagnose, stage and determine the likelihood of developing AD.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: July 21, 2020
    Assignee: ELECTROPHORETICS LIMITED
    Inventors: Ian Hugo Pike, Claire Louise Russell, Malcolm Ward
  • Patent number: 10709735
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: July 14, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
  • Patent number: 10711244
    Abstract: The present invention relates to a method for producing mammalian neural plate border stem cells (NPBSCs), comprising: (a) differentiation of mammalian pluripotent stem cells by (a-i) culturing mammalian pluripotent stem cells in pluripotent stem cell medium for about 24 to about 96 hours, wherein the pluripotent stem cell medium comprises: (i) an inhibitor of the activin/TGF-? signalling pathway; (ii) an inhibitor of the BMP signalling pathway; (iii) an activator of the canonical WNT signalling pathway; and (iv) an activator of the Hedgehog signalling pathway; subsequently (a-ii) culturing the cells obtained in step (a-i) for about 24 to about 96 hours in a neural medium, wherein the neural medium comprises: (i) an inhibitor of the Activin/TGF-? signalling pathway; (ii) an inhibitor of the BMP signalling pathway; (iii) an activator of the canonical WNT signalling pathway; and (iv) an activator of the Hedgehog signalling pathway; subsequently (a-iii) culturing the cells obtained in step (a-ii) for about 24 to
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: July 14, 2020
    Assignee: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Hans R. Schoeler, Jared L. Sterneckert, Michael Glatza, Peter Reinhardt
  • Patent number: 10711062
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: July 14, 2020
    Assignee: ALECTOR LLC
    Inventors: Patricia Culp, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Nels P. Nielson, Robert Pejchal
  • Patent number: 10702586
    Abstract: Provided herein are methods and compositions for treating disease-states associated with presence of increased number of ErbB4+ pro-inflammatory macrophages in a subject in need thereof. The methods include providing an activator of ErbB4 and administering a therapeutically effective amount of the activator to the subject. The compositions include an activator of ErbB4. In one embodiment, the activation of ErbB4 is Neuregulin-4.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: July 7, 2020
    Assignee: Children's Hospital Los Angeles
    Inventors: Mark R. Frey, Michael Schumacher
  • Patent number: 10688135
    Abstract: The present invention provides a composition for treating ischemic diseases or neuroinflammatory disorders, comprising a secretome of neural precursor cells (NPCs) as an active ingredient. The secretome of NPCs, of the present invention, reduces an ischemic injury site and enables neurological functions to recover by means of roles such as anti-inflammation, neovascularization regeneration, and activation and proliferation of inherent stem cells, thereby being usable as a therapeutic agent for ischemic diseases and degenerative nervous system disorders such as nerve damage diseases caused by inflammation. Particularly, the secretome of NPCs, of the present invention, has an excellent behavior improvement effect when administered multiple times.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: June 23, 2020
    Assignee: S-BIOMEDICS
    Inventors: Dong Wook Kim, Han Soo Kim
  • Patent number: 10688167
    Abstract: The described invention relates to a pharmaceutical composition comprising a therapeutically effect amount of a therapeutic agent, wherein the therapeutic agent is effective (1) to reduce tumor growth, migration, invasion or a combination and (2) improve subject survival relative to a control. The described invention also relates to a method of treating a subject with a tumor, the method comprising: (1) providing a pharmaceutical composition; and (2) administering the pharmaceutical composition, wherein the composition comprises a therapeutically effective amount of a therapeutic agent which is effective to reduce tumor growth, migration, invasion or a combination. The method may further comprise preparing therapeutic agent and preparing the pharmaceutical composition. The therapeutic agents include but are not limited to Wnt5a derivative peptides or Wnt5a antagonists or Wnt5a blocking antibody. The tumor comprises a population of cancer stem cells.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: June 23, 2020
    Assignee: HYPERSTEM SA
    Inventors: Angelo Luigi Vescovi, Elena Binda
  • Patent number: 10676715
    Abstract: Human pluripotent stem cells are differentiated in vitro into forebrain subdomain structures, which are then fused to generate an integrated system for use in analysis, screening programs, and the like.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: June 9, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jimena Andersen, Fikri Birey, Sergiu P. Pasca
  • Patent number: 10675328
    Abstract: Disclosed are compositions and methods of treating a neurodegenerative disease in an individual. The methods disclose administration of an Integrin ?4?1, Very Late Antigen-4 positive neural precursor cell (“VLA4+ NPC”) transfected with a lentivirus overexpressing wild type GCase to an individual having a neurodegenerative disorder. The neurodegenerative disease may include lipid storage diseases, for example Gaucher disease, Parkinson's disease (PD), Dementia with Lewy bodies.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: June 9, 2020
    Assignee: Children's Hospital Medical Center
    Inventor: Ying Sun